title: Benralizumab--a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma.
abstract: BACKGROUND
  Benralizumab is a monoclonal antibody that binds the α subunit of the receptor to IL-5. As IL-5 is implicated in disease states that are mediated by eosinophils, benralizumab is an attractive option for use in the management of asthma. As a result of enhanced antibody-directed cell cytotoxicity, it has enhanced eosinophil-depleting activity as compared with neutralizing monoclonal antibody directed against IL-5.
  
  
  METHODS
  This review presents the available data on benralizumab, including pharmacodynamics, pharmacokinetics, preclinical data and relevant clinical studies.
  
  
  CONCLUSIONS
  Our review indicates that although further investigation is necessary to demonstrate clinical benefit, benralizumab remains a promising treatment modality.
authors.affiliation: University of Texas Medical Branch, Division of Allergy and Clinical Immunology, 4.118 John Sealy Annex, 301 University Blvd, Galveston, TX 77555-0568, USA.
authors.forename: Aasia
authors.initials: A
authors.lastname: Ghazi
authors.forename: Anita
authors.initials: A
authors.lastname: Trikha
authors.forename: William J
authors.initials: WJ
authors.lastname: Calhoun
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D057134:Antibodies, Neutralizing / Q000737:chemistry; D001249:Asthma / Q000276:immunology / Q000628:therapy*; D002986:Clinical Trials as Topic; D004804:Eosinophils / Q000187:drug effects; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007249:Inflammation; D015848:Interleukin-5 / Q000737:chemistry; D053666:Interleukin-5 Receptor alpha Subunit / Q000737:chemistry* / Q000276:immunology; D008954:Models, Biological; D008957:Models, Genetic; D010641:Phenotype; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D057134:Antibodies, Neutralizing; D015848:Interleukin-5; D053666:Interleukin-5 Receptor alpha Subunit; C571386:benralizumab